These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28334974)

  • 41. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
    Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Verzoni E; Grassi P; Montone R; Galli G; Necchi A; Procopio G
    Tumori; 2015; 101(6):701-3. PubMed ID: 26108242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
    Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
    Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
    Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
    Beaumont JL; Butt Z; Baladi J; Motzer RJ; Haas T; Hollaender N; Kay A; Cella D
    Oncologist; 2011; 16(5):632-40. PubMed ID: 21459902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
    N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
    Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
    Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
    Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
    N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors.
    Kumano M; Miyake H; Harada K; Fujisawa M
    Med Oncol; 2013 Dec; 30(4):745. PubMed ID: 24122255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study.
    Tomita Y; Fukasawa S; Shinohara N; Kitamura H; Oya M; Eto M; Tanabe K; Saito M; Kimura G; Yonese J; Yao M; Uemura H
    Jpn J Clin Oncol; 2019 Jun; 49(6):506-514. PubMed ID: 30941424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
    Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
    Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ).
    Schostak M; de Geeter P; Decker T; Resch A; Quiering C; Schmitz S
    Urol Int; 2020; 104(3-4):263-268. PubMed ID: 31726458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
    Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.